CCCC - C4 Therapeutics Inc Stock Price, Fair Value and News

6.86USD-0.55 (-7.42%)Market Closed

Market Summary

USD6.86-0.55

Market Closed

-7.42%

CCCC Stock Price

View Fullscreen

CCCC RSI Chart

CCCC Valuation

Market Cap

470.6M

Price/Earnings (Trailing)

-3.55

Price/Sales (Trailing)

22.67

EV/EBITDA

-2.71

Price/Free Cashflow

-4.34

CCCC Price/Sales (Trailing)

CCCC Profitability

EBT Margin

-624.66%

Return on Equity

-53.83%

Return on Assets

-35.2%

Free Cashflow Yield

-23.07%

CCCC Fundamentals

CCCC Revenue

Revenue (TTM)

20.8M

Rev. Growth (Yr)

14.26%

Rev. Growth (Qtr)

-70.55%

CCCC Earnings

Earnings (TTM)

-132.5M

Earnings Growth (Yr)

6.54%

Earnings Growth (Qtr)

-28.54%

Breaking Down CCCC Revenue

Last 7 days

-10.4%

Last 30 days

-23.2%

Last 90 days

0.2%

Trailing 12 Months

104.8%

How does CCCC drawdown profile look like?

CCCC Financial Health

Current Ratio

6.34

CCCC Investor Care

Shares Dilution (1Y)

39.86%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	27.2M	16.0M	20.3M	20.8M
2022	46.0M	50.1M	48.3M	31.1M
2021	33.8M	33.9M	34.0M	45.8M
2020	24.3M	27.3M	30.2M	33.2M
2019	0	0	0	21.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of C4 Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	anderson kenneth carl	acquired	11,250	8.1	1,389	-
Apr 01, 2024	grogan donna roy	acquired	13,745	8.1	1,697	-
Apr 01, 2024	dubin glenn	acquired	10,999	8.1	1,358	-
Feb 15, 2024	hirsch andrew	sold (taxes)	-51,824	7.9	-6,560	president & ceo
Feb 14, 2024	mossler mark	acquired	-	-	18,290	chief accounting officer
Feb 14, 2024	adams kendra	acquired	-	-	36,700	chief financial officer
Feb 14, 2024	reyno leonard	acquired	-	-	36,700	chief medical officer
Feb 14, 2024	siegel jolie	acquired	-	-	27,300	chief legal officer
Feb 14, 2024	boyle scott n	acquired	-	-	27,300	chief business officer
Feb 14, 2024	fisher stewart	acquired	-	-	27,300	chief scientific officer

Which funds bought or sold CCCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	3.87	7,716,380	11,296,600	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	3.8	875,873	1,282,700	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	17.01	10,390,000	14,457,000	-%
Feb 16, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	sold off	-100	-132,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	1,122,490	1,122,490	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-1,860,000	-	-%
Feb 15, 2024	BARCLAYS PLC	added	-	166,000	247,000	-%
Feb 14, 2024	ALGERT GLOBAL LLC	reduced	-45.98	62,000	158,000	0.01%
Feb 14, 2024	MARSHALL WACE, LLP	new	-	6,345,300	6,345,300	0.01%
Feb 14, 2024	Mariner, LLC	added	1.22	488,136	723,409	-%

Are Funds Buying or Selling CCCC?

Are funds buying CCCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CCCC

No. of Funds

Unveiling C4 Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	10.43%	7,153,280	SC 13G
Mar 08, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.4%	3,134,396	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	5.2%	2,558,480	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 05, 2024	soleus capital master fund, l.p.	5.2%	2,555,996	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	3.7%	1,835,996	SC 13G/A
Jan 12, 2024	betta investment (hong kong) ltd.	8.1%	5,567,928	SC 13G
Jan 04, 2024	point72 asset management, l.p.	4.7%	2,312,059	SC 13G

Recent SEC filings of C4 Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	SC 13G/A	Major Ownership Report
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to C4 Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

C4 Therapeutics Inc News

Latest updates

C4 Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-70.5%	3,261,000	11,072,000	2,664,000	3,759,000	2,854,000	6,754,000	13,834,000	7,654,000	20,078,000	8,500,000	9,781,000	7,426,000	8,262,000	8,447,000	9,670,000	6,816,000	6,090,000	5,364,000
Operating Expenses	4.7%	40,688,000	38,880,000	40,232,000	39,987,000	41,147,000	39,242,000	41,218,000	39,023,000	35,333,000	32,754,000	31,897,000	27,935,000	27,165,000	26,796,000	20,529,000	19,154,000	-	15,365,000
S&GA Expenses	-2.2%	10,297,000	10,533,000	10,306,000	10,945,000	10,495,000	9,579,000	9,895,000	12,820,000	8,782,000	8,452,000	8,611,000	7,409,000	6,732,000	2,861,000	2,769,000	2,842,000	-	2,417,000
R&D Expenses	7.2%	30,391,000	28,347,000	29,926,000	29,042,000	30,652,000	29,663,000	31,323,000	26,203,000	26,551,000	24,302,000	23,286,000	20,526,000	20,433,000	23,935,000	17,760,000	16,312,000	-	12,948,000
EBITDA Margin	-0.7%	-6.11	-6.07	-7.77	-4.59	-4.02	-1.90	-1.83	-1.99	-1.77	-2.58	-2.51	-2.17	-	-	-	-	-	-
Interest Expenses	-100.0%	-	138,000	422,000	430,000	421,000	375,000	355,000	473,000	238,000	363,000	349,000	358,000	-	-	-	-	-	-
Income Taxes	-72.1%	280,000	1,003,000	-	-	-	-	-	-	-	-	-	-	-124,000	-167,000	-168,000	-167,000	-	650,000
Earnings Before Taxes	-32.4%	-34,477,000	-26,034,000	-	-	-37,185,000	-31,958,000	-	-31,620,000	-15,658,000	-24,683,000	-22,580,000	-20,971,000	-21,919,000	-22,002,000	-10,961,000	-12,079,000	-	-9,444,000
EBT Margin	-0.2%	-6.25	-6.23	-8.00	-4.71	-4.12	-1.96	-1.89	-2.05	-1.83	-2.65	-2.58	-2.24	-	-	-	-	-	-
Net Income	-28.5%	-34,754,000	-27,037,000	-35,922,000	-34,780,000	-37,185,000	-31,958,000	-27,412,000	-31,620,000	-15,658,000	-24,683,000	-22,580,000	-20,971,000	-21,795,000	-21,835,000	-10,793,000	-11,912,000	-	-10,094,000
Net Income Margin	3.7%	-6.38	-6.63	-8.72	-4.83	-4.12	-2.21	-1.98	-2.05	-1.83	-2.65	-2.57	-2.23	-	-	-	-	-	-
Free Cashflow	22.8%	-24,166,000	-31,307,000	-19,359,000	-33,714,000	-30,618,000	-31,325,000	-22,724,000	-26,768,000	-25,780,000	-18,358,000	-18,749,000	-25,355,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	13.0%	376	333	375	396	431	461	492	515	507	508	528	374	400	229	118
Current Assets	21.2%	271	224	274	278	288	325	318	303	326	412	478	322	381	209	97.00
Cash Equivalents	107.6%	127	61.00	45.00	49.00	30.00	50.00	57.00	46.00	79.00	163	281	95.00	184	63.00	91.00
Net PPE	-2.2%	7.00	7.00	8.00	8.00	7.00	7.00	6.00	3.00	3.00	3.00	4.00	4.00	3.00	4.00	4.00
Liabilities	11.4%	130	117	141	134	142	143	148	151	117	109	112	110	119	129	119
Current Liabilities	41.3%	43.00	30.00	48.00	39.00	45.00	45.00	46.00	47.00	51.00	49.00	44.00	38.00	44.00	40.00	34.00
Long Term Debt	-	-	-	-	9.00	9.00	9.00	10.00	10.00	11.00	11.00	10.00	10.00	10.00	10.00	-
LT Debt, Current	-	-	-	10.00	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	9.00	9.00	9.00	10.00	10.00	11.00	11.00	10.00	10.00	10.00	10.00	-
Shareholder's Equity	13.9%	246	216	234	262	289	318	345	365	390	399	416	264	281	-	-
Retained Earnings	-7.0%	-528	-493	-466	-430	-395	-358	-326	-299	-267	-252	-227	-204	-183	-162	-117
Additional Paid-In Capital	9.0%	775	711	702	696	689	682	676	668	658	651	644	469	465	6.00	6.00
Shares Outstanding	22.8%	60.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	48.00	43.00	43.00	-	-	-
Float	-	-	-	130	-	-	-	201	-	-	-	1,278	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	21.8%	-24,009	-30,707	-18,997	-33,125	-29,128	-28,020	-22,195	-26,596	-25,671	-18,358	-18,002	-24,934	-21,593	-14,396	-14,594	-16,666	-	-
Share Based Compensation	-22.5%	6,359	8,200	6,425	6,251	6,919	6,011	8,148	8,938	6,353	6,086	5,228	3,845	2,719	436	161	116	-	-
Cashflow From Investing	-44.7%	31,945	57,725	15,148	53,531	9,284	19,914	33,228	-4,004	-59,413	-100,627	32,434	-61,730	-54,167	-32,321	-103,833	-184	-	-
Cashflow From Financing	636.3%	57,672	-10,753	-746	-684	47.00	361	259	480	466	584	170,501	-151	194,053	2,499	152,224	156	-	-
Buy Backs	-100.0%	-	16.00	-	94.00	-	-	-	-	-	-	-	-	-16.00	86.00	-78.00	202	-	6.00

CCCC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue from collaboration agreements	$ 20,756	$ 31,096
Operating expenses:
Research and development	117,706	117,841
General and administrative	42,081	42,789
Total operating expenses	159,787	160,630
Loss from operations	(139,031)	(129,534)
Other income (expense), net
Interest expense and amortization of long-term debt—related party	(1,373)	(2,216)
Loss on early extinguishment of debt	(621)	0
Interest and other income, net	9,812	3,575
Total other income (expense), net	7,818	1,359
Loss before income taxes	(131,213)	(128,175)
Income tax expense	(1,280)	0
Net loss	$ (132,493)	$ (128,175)
Net loss per share — basic (in dollars per share)	$ (2.67)	$ (2.62)
Net loss per share — diluted (in dollars per share)	$ (2.67)	$ (2.62)
Weighted-average number of shares - basic (in shares)	49,640,505	48,861,665
Weighted-average number of shares - diluted (in shares)	49,640,505	48,861,665
Other Comprehensive gain (loss):
Unrealized gain (loss) on marketable securities	$ 4,010	$ (3,362)
Comprehensive loss	$ (128,483)	$ (131,537)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaborative Arrangement [Member]	Collaborative Arrangement [Member]

CCCC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 126,590	$ 29,754
Marketable securities, current	127,091	246,399
Accounts receivable	11,799	1,473
Prepaid expenses and other current assets	5,709	9,931
Total current assets	271,189	287,557
Marketable securities, non-current	28,008	60,962
Property and equipment, net	7,132	7,400
Right-of-use asset	63,956	70,116
Restricted cash	3,443	3,279
Other assets	2,723	1,526
Total assets	376,451	430,840
Current liabilities:
Accounts payable	1,446	1,172
Accrued expenses and other current liabilities	20,630	19,769
Deferred revenue, current	15,471	16,618
Operating lease liability, current	5,219	4,700
Long-term debt, net of debt discount—related party, current	0	2,287
Total current liabilities	42,766	44,546
Deferred revenue, net of current	21,814	16,895
Operating lease liability, net of current	65,757	70,970
Long-term debt, net of debt discount—related party, net of current	0	9,195
Total liabilities	130,337	141,606
Commitments and contingencies (See Note 6 and Note 9)
Stockholders’ equity:
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 60,467,188 and 48,966,216 shares issued and outstanding as of December 31, 2023 and 2022, respectively	6	5
Additional paid-in capital	774,618	689,256
Accumulated other comprehensive loss	(127)	(4,137)
Accumulated deficit	(528,383)	(395,890)
Total stockholders’ equity	246,114	289,234
Total liabilities and stockholders’ equity	$ 376,451	$ 430,840

About C4 Therapeutics Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Mr. Andrew J. Hirsch M.B.A.
WEBSITE	c4therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	146

C4 Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for C4 Therapeutics Inc? What does CCCC stand for in stocks?

CCCC is the stock ticker symbol of C4 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of C4 Therapeutics Inc (CCCC)?

As of Mon Apr 15 2024, market cap of C4 Therapeutics Inc is 470.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers. The fair value of C4 Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of C4 Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CCCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is C4 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CCCC is over valued or under valued. Whether C4 Therapeutics Inc is cheap or expensive depends on the assumptions which impact C4 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCCC.

What is C4 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, CCCC's PE ratio (Price to Earnings) is -3.55 and Price to Sales (PS) ratio is 22.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCCC PE ratio will change depending on the future growth rate expectations of investors.